[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nras-q61k\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nras-q61k":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100638139",false,"NCT07584226","A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors","A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Histologically confirmed diagnosis of unresectable Stage III or IV melanoma or other solid tumor.\n* Disease is refractory to standard therapy (including targeted therapy), participant is intolerant of standard therapy, or participant has declined standard therapy.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* One or more documented primary oncogenic NRAS mutation(s).\n\nExclusion Criteria:\n\n* Known activating KRAS, HRAS, or BRAF mutation or known alterations in other driver oncogenes.\n* Prior treatment with ERK, MEK, RAF, or RAS targeting agents or any agent whose mechanism of action is to inhibit the RAS-MAPK pathway.\n* For participants with melanoma: lactate dehydrogenase (LDH) \\>2×ULN.\n* Central nervous system (CNS) metastases that are associated with progressive neurologic symptoms or require ongoing corticosteroids to control the CNS disease.","ALL","18 Years",{"count":18,"type":19},35,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.",[25,26,27,28,29,30,31,32,33,34,35],"Advanced NRAS-Mutant Melanoma","Advanced NRAS-Mutant Solid Tumors","NRAS Mutation","NRAS G12D","NRAS G13R","NRAS G13D","NRAS G12V","NRAS Q61R","NRAS Q61K","NRAS Q61L","NRAS Q61H","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-03-09",{"date":44,"type":19},"2029-12-31",{"name":46,"class":47},"Relay Therapeutics, Inc.","INDUSTRY",9,""]